Why ABION’s ABN202 may be aiming beyond TROP2 antibody-drug conjugate resistance

ABION’s ABN202 showed preclinical promise against TROP2 ADC resistance at AACR 2026. Read what this could mean for solid tumor oncology.

ABION’s ABN202 showed preclinical promise against TROP2 ADC resistance at AACR 2026. Read what this could mean for solid tumor oncology.